(Q34486930)

2 August 2017

0 references

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials (English)

1 reference

Early Breast Cancer Trialists' Collaborative Group

2 August 2017

0 references

0 references

0 references

0 references

1 reference

series ordinal

1

object named as

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

1 reference

ORCID Public Data File 2021

2 August 2017

1 reference

language of work or name

English

0 references

publication date

23 July 2015

1 reference

2 August 2017

1 reference

2 August 2017

386

1 reference

2 August 2017

10001

1 reference

2 August 2017

1341-1352

1 reference

PubMed ID

26211827

describes a project that uses

2 August 2017

meta-analysis

0 references

cites work

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961074-1

7 January 2021

10.1016/S0140-6736(15)61074-1

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

26211827